Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor Phase III trial in NASH with fibrosis
NL-OMON50213Phase 3Active, not recruiting
- Sponsor
- Genfit
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Elafibranor with Placebo (2 arms). Primary endpoints: Resolution of NASH without worsening of fibrosis at 72 weeks and Composite long-term clinical outcome endpoint. Started Aug 2016; status: active, not recruiting.
02
Drugs
elafibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON50213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50213.